Drug Manufacturing, Drug Delivery, Clinical Trials News

Molecular Profiles invests in new facility to increase manufacturing capabilities for clinical trials

Molecular Profiles, a leading specialist contract research and manufacturing organization, announces the commencement of construction of a new manufacturing facility. This £9 million investment will allow Molecular Profiles to expand its current manufacturing capabilities while strengthening its existing expertise in the drug development field.
Dr Reddy’s Laboratories completes first implementation phase of Werum’s standard MES

Dr Reddy’s is the first Indian company to improve its manufacturing processes by installing an electronic PAS-X Manufacturing Execution System (MES). Dr Reddy’s opted for Werum’s MES PAS-X to help enhance the quality and compliance and to optimize the efficiency and productivity of its pharmaceutical shop floor processes.
Agilent Technologies, Integrated Diagnostics enter into partnership

Agilent Technologies and Integrated Diagnostics announced a partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.
Gerresheimer wins German Packaging Award for multilayer plastic vials

Gerresheimer has received the German Packaging Award 2011 in the Retail Packaging category for developing vials which offer previously unattained levels of safety for parenteral drugs. Gerresheimer’s multilayer plastic vials unite the best properties of plastic and glass in a high quality packaging for liquid medications.
US government HIV/AIDS clinical trial sites to accelerate completion of Phase III TB drug trial

The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases’ (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.
ViroMed receives approval for Phase II trial in the US for diabetic peripheral neuropathy

ViroMed announced that VM202-DPN, the company's proprietary DNA medicine for treatment of diabetic peripheral neuropathy, has received approval from the US FDA for a Phase II clinical trial.